Does Anti Platelet Agents Interact with Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen?
Anti Platelet Agents and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen have a major drug interaction according to U.S. FDA drug labeling data. Drugs that induce P-gp activity may decrease TAF absorption, resulting in decreased plasma concentration and loss of therapeutic effect with possible resistance development. The mechanism involves taf is a substrate of p-gp; induction decreases absorption. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Anti Platelet Agents and Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen occurs because taf is a substrate of p-gp; induction decreases absorption. Clinically, this means drugs that induce p-gp activity may decrease taf absorption, resulting in decreased plasma concentration and loss of therapeutic effect with possible resistance development. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Anti Platelet Agents and your doctor is considering prescribing Emtricitabine Rilpivirine Hydrochloride And Tenofovir Alafen (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider